If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 61 - 70 of 270
Evaluating Pre-Treatment Vestibular Physical Therapy Rehab for Patients with Vestibular Schwannomas
Objective
Evaluating Pre-Treatment Vestibular Physical Therapy Rehab for Patients With Vestibular Schwannomas (VS PREHAB)
Protocol No
IIT-HARRIS-PREHAB-VS
Categories
Advanced Imaging Biomarkers of Hand Dysfunction and Recovery in Individuals with Enhancing Brain Lesions
Objective
Hand Function in Brain Tumors
Protocol No
IIT-KRUCOFF-HAND-FUNCTION
Categories
An Open-label Phase I/II Trial of Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Systemic Light-Chain Amyloidosis
Objective
A Phase I/II Trial of Venetoclax + Dexamethasone in R/R Systemic Light-Chain Amyloidosis
Protocol No
COLUMBIAUNIVERSITY-AAAT8639
Categories
A Phase III, Open-Label, Randomized Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxi
Objective
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy (CAMBRIA-1)
Protocol No
AZ-NSABP-D8531C00002-CAMBRIA
Categories
A Phase 3b, Open-label Study Evaluating the Efficacy and Safety of Luspatercept (BMS-986346/ACE-536) Initiated at Maximum Approved Dose in LR-MDS with IPSS-R Very Low-, Low-, or Intermediate-risk Who Require RBC Transfusions (MAXILUS)
Objective
Study of Luspatercept in lower-risk myelodysplastic syndrome participants
Protocol No
BMS-CA0561060
Categories
A Open-label, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of Epcoritamab and Rituximab for Patients with Untreated Follicular Lymphoma (FL)
Objective
A phase 2 study of Epcoritamab and Rituximab for first-line treatment of follicular lymphoma.
Protocol No
DFCI-22-702
Categories
Molecular Profile-related Individualized Targeted Therapy in Resected Pancreatic Cancer with High-Risk of Cancer Recurrence (PROTECT-PANC)
Objective
Molecular Profile-related Individualized Targeted Therapy in Resected Pancreatic Cancer With High-Risk of Cancer Recurrence (PROTECT-PANC)
Protocol No
IIT-KAMGAR-PROTECT-PANC
Categories
Phase II Trial to Determine Role of Nodal Radiation Therapy after Sentinel Lymph Node Biopsy (SLNB) for Patients with High-Risk Sentinel Lymph Node Positive Melanoma Who Are Planned for Immunotherapy without Completion of Lymph Node Dissection (MelPO
Objective
The role of nodal radiation therapy in sentinel lymph node positive melanoma
Protocol No
MDA-2020-0148
Categories
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ficlatuzumab in Combination with Cetuximab in Participants with Recurrent or Metastatic (R/M) HPV-Negative Head and Neck Squamous Cell Carcinoma (FIERCE-HN)
Objective
Ficlatuzumab in Combination with Cetuximab in Participants with Recurrent or Metastatic (R/M) HPV-Negative Head and Neck Squamous Cell Carcinoma (FIERCE-HN)
Protocol No
AVEO-AV-299-23-301
Categories
PROmoting CLinicAl TrIal EngageMent for Pancreatic Cancer App Study (PROCLAIM Study)
Objective
Promoting CT Engagement for Pancreatic Cancer With App (PROCLAIM)
Protocol No
UNC-LCCC2234-PROCLAIM
Categories